LEXINGTON, Mass., May 22, 2025 /PRNewswire/ -- Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer therapeutics, today announced that ...

REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ...

TNX-1900 and TNX-2900 may serve as novel neuroendocrine treatments for certain pain, eating and endocrine disorders. CHATHAM, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding ...

CinFina Pharma Presents Positive Phase 1 Study Results in Poster Session for CIN-109 and in Late-Breaking ... CIN-110 is a novel, long-acting PYY 3-36 analog designed to significantly ...

Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting Provided by ...

Novel study reveals how aging immune system fuels cancer growth, potentially opening new avenues for prevention. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2024 ...

The findings, published in the journal Nature and supported by the National Institutes of Health and U.S. National Science Foundation, provide novel insights on how brain wiring changes during ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes ...

A Phase 1 dose escalation study was concluded as a monotherapy and in combination with cetuximab, ... today announced a poster presentation on its novel CAPTN-3 tri-specific antibody platform, ...

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform Provided by GlobeNewswire Jun 4, 2025, 11:00:00 AM ...